{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:53:02Z","timestamp":1790409182546,"version":"4.1.0"},"reference-count":22,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,12,30]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common adverse event of CD19-directed chimeric antigen receptor (CAR) T cell therapy. Other neurological adverse events, however, have not methodically been described and studied. Furthermore, safety data on CAR-T cell therapy in patients with central nervous system (CNS) lymphoma remain limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main body<\/jats:title>\n                  <jats:p>We here report occurrence of a Guillain-Barr\u00e9-like syndrome (GBS) and central diabetes insipidus (cDI) following tisagenlecleucel therapy for relapsed high-grade lymphoma with CNS involvement. Both complications were refractory to standard treatment of ICANS. Weakness of respiratory muscles required mechanical ventilation and tracheostomy while cDI was treated with desmopressin substitution for several weeks. Muscle-nerve biopsy and nerve conduction studies confirmed an axonal pattern of nerve damage. T cell-rich infiltrates and detection of the CAR transgene in muscle-nerve sections imply a direct or indirect role of CAR-T cell-mediated inflammation. In line with current treatment guidelines for GBS, intravenous immunoglobulin was administered and gradual but incomplete recovery was observed over the course of several months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This case report highlights the risk of rare but severe neurological adverse events, such as acute GBS or cDI, in patients treated with CAR-T cells. It further underlines the importance of appropriate patient surveillance and systematic reporting of rare complications to eventually improve treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-006059","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T10:00:14Z","timestamp":1674468014000},"page":"e006059","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Diabetes insipidus and Guillain-Barr\u00e9-like syndrome following CAR-T cell therapy: a case report"],"prefix":"10.1136","volume":"11","author":[{"given":"Christian","family":"Koch","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Fleischer","sequence":"additional","affiliation":[{"name":"Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todor","family":"Popov","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Frontzek","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, University Hospital and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Schreiner","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus G.","family":"Manz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Unseld","sequence":"additional","affiliation":[{"name":"Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia M. S.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3090-7186","authenticated-orcid":false,"given":"Norman F.","family":"Russkamp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland"},{"name":"Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"2025100304303184000_11.1.e006059.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"2025100304303184000_11.1.e006059.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100304303184000_11.1.e006059.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"2025100304303184000_11.1.e006059.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.022"},{"key":"2025100304303184000_11.1.e006059.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694"},{"key":"2025100304303184000_11.1.e006059.6","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12640"},{"key":"2025100304303184000_11.1.e006059.7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2025100304303184000_11.1.e006059.8","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"2025100304303184000_11.1.e006059.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9"},{"key":"2025100304303184000_11.1.e006059.10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41572-019-0103-2","article-title":"Diabetes insipidus","volume":"5","author":"Christ-Crain","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025100304303184000_11.1.e006059.11","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3324\/haematol.2020.259952","article-title":"Acute leucoencephalomyelopathy and quadriparesis after car T-cell therapy","volume":"106","author":"Nair","year":"2021","journal-title":"Haematologica"},{"key":"2025100304303184000_11.1.e006059.12","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1200\/JCO.1994.12.10.2216","article-title":"Neurotoxicity of purine analogs: a review","volume":"12","author":"Cheson","year":"1994","journal-title":"J Clin Oncol"},{"key":"2025100304303184000_11.1.e006059.13","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/bjc.1994.430","article-title":"Neurological illness following treatment with fludarabine","volume":"70","author":"Johnson","year":"1994","journal-title":"Br J Cancer"},{"key":"2025100304303184000_11.1.e006059.14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","article-title":"Fludarabine and neurotoxicity in engineered T-cell therapy","volume":"25","author":"Lowe","year":"2018","journal-title":"Gene Ther"},{"key":"2025100304303184000_11.1.e006059.15","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389607293"},{"key":"2025100304303184000_11.1.e006059.16","article-title":"Variant Guillain-Barr\u00e9 syndrome in a patient with non-Hodgkin's lymphoma","volume":"2015","author":"Bishay","year":"2015","journal-title":"Case Rep Hematol"},{"key":"2025100304303184000_11.1.e006059.17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0759-x"},{"key":"2025100304303184000_11.1.e006059.18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001155"},{"key":"2025100304303184000_11.1.e006059.19","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9800488","article-title":"Guillain-Barr\u00e9 syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases","volume":"2021","author":"Li","year":"2021","journal-title":"Biomed Res Int"},{"key":"2025100304303184000_11.1.e006059.20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01905"},{"key":"2025100304303184000_11.1.e006059.21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/imt-2020-0334","article-title":"Anti-PD-1 treatment-induced immediate central diabetes insipidus: a\u00a0case report","volume":"13","author":"Yu","year":"2021","journal-title":"Immunotherapy"},{"key":"2025100304303184000_11.1.e006059.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-006059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:30:41Z","timestamp":1759491041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,23]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/jitc-2022-006059"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-006059","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}